Moderna is trading at $57.19, up +6.26%, on August 7, 2026, after the FDA approved mFlusiva, its seasonal mRNA flu vaccine for adults aged 50 and older.

  • The approval covers ages 50–64 traditionally and ages 65-plus through an accelerated pathway.
  • Moderna’s first seasonal flu product is expected for the 2026–27 respiratory season, a significant commercial and pipeline catalyst.
  • XBI ETF is up 2.09%, supporting sector momentum, but the FDA decision is the clearer primary driver.